This Week's Biotech Catalysts

Placebo Phase 3 Results Expected

Placebo • Hypertension

Mibavademab Phase 2 Results Expected

Mibavademab • Obesity

Tirzepatide Phase 2 Results Expected

Tirzepatide • Overweight

Mevidalen Phase 2 Results Expected

Mevidalen • Alzheimer Disease

Selinexor (combination therapy) Phase 3 Results Expected

Selinexor (combination therapy) • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Placebo Phase 3 Results Expected

Placebo • Focal Onset Seizures

lorundrostat Phase 3 Results Expected

Lorundrostat • Obstructive Sleep Apnea

TNG908 Phase 2 Results Expected

TNG908 • Locally Advanced Solid Tumor

Pegtibatinase Phase 3 Results Expected

Pegtibatinase • Homocystinuria

Solriamfetol 150 mg Phase 3 Results Expected

Solriamfetol 150 mg • Excessive Sleepiness

Ratutrelvir (83-0060) non-randomised Phase 2 Results Expected

Ratutrelvir (83-0060) non-randomised • COVID - 19

Solriamfetol 300 mg Phase 3 Results Expected

Solriamfetol 300 mg • Binge-Eating Disorder

KB801 Phase 2 Results Expected

KB801 • Neurotrophic Keratitis

Lorundrostat Phase 2 Results Expected

Lorundrostat • Obstructive Sleep Apnea

BNT142 Phase 2 Results Expected

BNT142 • Solid Tumor

Ixekizumab Phase 3 Results Expected

Ixekizumab • Psoriasis

Tipifarnib Phase 2 Results Expected

Tipifarnib • HNSCC

XEN1101 Phase 3 Results Expected

XEN1101 • Primary Generalized Tonic-Clonic Seizures

CHAMPIONS Reports Financial Results

Placebo Phase 3 Results Expected

Placebo • Obesity

Setmelanotide Phase 3 Results Expected

Setmelanotide • Genetic Obesity

LP-300 Phase 2 Results Expected

LP-300 • Adenocarcinoma of Lung

QTORIN 3.9% rapamycin anhydrous gel Phase 2 Results Expected

QTORIN 3.9% Rapamycin Anhydrous Gel • Microcystic Lymphatic Malformation

Aglatimagene besadenovec Phase 2 Results Expected

aglatimagene besadenovec • Prostate Cancer